Ann: FDA Breakthrough Device Designation, page-192

INVESTOR RELATIONSTransparent Communication for a Fair Valuation
"The Company continues to work on increasing awareness for its shares and its equity story in the financial community and recognises the value of regular dialogue with its shareholders. Our goal is to ensure we communicate the Company’s strategy and achievements reliably and transparently to gain investor confidence and achieve a fair valuation of its shares. Throughout the year, management and certain Directors, travelled throughout Australia and held periodic investor conference calls to apprise investors and brokers of our business progress. Subsequent to the end of the fiscal year, management presented at the AusBiotech Asian Investor meetings in Hong Kong and Shanghai. During those events management held numerous one-on-one meetings with potential new international investors and strategic partners. We make a concerted effort to ensure shareholders have been informed about current developments via regular press releases, a Newsletter and use of social media.8As we move toward the “clinical phase” of our journey, we will need to raise additional capital. While accessing “non-dilutive” forms of capital, such as tax credits, grants and revenue remains a priority, we will be required to sell additional shares to support continued progress. With recognition that we are undervalued in the market, we will redouble our efforts to communicate with investors and build awareness about the promise of Imagion’s technology and the progress we are makin"